Emyria has trained its first cohort of 31 clinicians in New South Wales, paving the way for its inaugural Sydney Empax clinic at Matilda Nepean, scheduled to open in Q3 2026.
- 31 NSW clinicians trained for Empax therapy delivery
- Sydney clinic opening on track for Q3 2026
- NSW represents Australia’s largest mental health patient market
- National clinical workforce exceeds 100 trained therapists and psychiatrists
- Operational preparations including medication and fit-out underway
NSW Clinician Training Marks Key Expansion Milestone
Emyria Limited (ASX:EMD) has completed training for its first cohort of 31 contracted clinicians in New South Wales, a critical step ahead of opening its first Sydney Empax clinic at Matilda Nepean in the third quarter of 2026. This group includes 25 therapists and 6 psychiatrists who underwent the company’s Empax training program over a recent weekend, joining a national network of over 100 trained clinicians across Western Australia, Victoria, and Queensland.
The training initiative follows a recruitment campaign launched in April and represents the groundwork for establishing Emyria’s fourth state-based clinical operation. The Sydney clinic will expand the company’s footprint into Australia’s largest addressable mental health market, where demand for innovative, evidence-based therapies is rising sharply.
Sydney Clinic Progressing on Schedule
Alongside workforce development, Emyria is finalising operational essentials for the Sydney clinic. Medication supplies have been secured, and the fit-out at Matilda Nepean Private Hospital is nearing completion. The company remains confident in meeting its Q3 2026 timeline for the clinic’s launch, which will add to existing facilities in Perth, Brisbane, and Melbourne.
NSW’s mental health landscape underscores the clinic’s potential impact. Over 1.8 million residents live with long-term mental or behavioural conditions, and psychological injuries have surged by 64% since 2019-20. Emyria’s Executive Director Greg Hutchinson highlighted the strategic importance of this expansion, stating the company is positioned to deliver new therapies to patients with complex mental health needs.
Building on National Growth and Regulatory Support
This milestone aligns with Emyria’s broader national growth strategy, which has seen the company expand its Empax clinic network and benefit from regulatory developments. Recent changes by the Therapeutic Goods Administration have broadened the range of clinicians eligible to provide psychedelic-assisted psychotherapy, a factor expected to accelerate recruitment and improve clinic utilisation across states.
Emyria’s approach integrates clinical service delivery with treatment development, focusing on therapies such as MDMA and psilocybin-assisted psychotherapy. While these treatments are still subject to clinical trial evaluation and regulatory approval, Emyria continues to build its capacity to meet growing patient demand through trained specialists and expanding clinic infrastructure.
Bottom Line?
Emyria’s NSW clinician training and clinic preparations signal tangible progress in accessing Australia’s largest mental health market, but the real test will be patient uptake and regulatory approvals in the coming quarters.
Questions in the middle?
- How quickly will the Sydney clinic reach operational breakeven given NSW’s large patient base?
- Will ongoing regulatory changes further expand the pool of eligible therapists beyond psychiatrists and therapists?
- How will patient outcomes and demand in NSW compare with Emyria’s existing clinics in other states?